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Abstract 
Review on MIR135A1, with data on DNA/RNA 
and where the gene is implicated. 
Identity 
Other names: MIRN135-1, MIRN135A1 
HGNC (Hugo): MIR135A1 
Location: 3p21.1 
Local order: Genes flanking MIR135A1 oriented 
from centromere to telomere on 3p21.1:  
- PHF7: PHD finger protein 7, 3p21.1 
- BAP1: BRCA1 associated protein-1 (ubiquitin 
carboxy-terminal hydrolase), 3p21.31-p21.2 
- DNAH1: dynein, axonemal, heavy chain 1, 
3p21.1 
- MIR135A1 
- GLYCTK-AS1: GLYCTK Antisense RNA 1 
(Non-protein coding), 3p21.1 
 
- GLYCTK: glycerate kinase, 3p21.1 
- TCONS_00006853; lnc-GLYCTK-1, 3p21.1 
- WDR82: WD repeat domain 82, 3p21.2 
- MIRLET7G: microRNA let-7g, 3p21.1. 
DNA/RNA 
Description 
The gene is located in the intron 1 of GLYCTK-
AS1/RP11 gene (sense) and in the exon 4 of 
GLYCTK (antisense). The precursor length is 90 
nt. 
Transcription 
The transcription of miR-135a is regulated by 
FOXM1 in hepatocellular carcinoma (Liu et al., 
2012). BMP2 inhibits miR-135a expression during 
osteoblast differentiation (Li et al., 2008). 
Pseudogene 
No reported pseudogenes. 
 
Stem-loop structure of hsa-mir-135a-1.  
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MicroRNAs are not translated into amino acids. 
Mutations 
Note 
Deletions of miR-135a-1 gene have been described 
in medulloblastomas, where 16/48 (33%) of 
medulloblastoma patients had a deletion of miR-
135a-1 gene (Lv et al., 2012). 
Implicated in 
Cancer 
Colorectal cancer (CRC) 
Note 
Interestingly, treating CRC cell lines with mistletoe 
lecitin-I, degrades precursor of some microRNAs, 
including pre-mir-135a, thus dowregulating miR-
135 and upregulating APC and increasing beta-
catenin phosphorylation (Li et al., 2011). 
Prognosis 
A prognostic miRNA signature composed of miR-
135a, miR-21, miR-335, miR-206 and let-7a was 
useful to detect the presence of metastasis (Vickers 
et al., 2012). 
Oncogenesis 
Oncogene.  
miRNA expression: Overexpression among 
colorectal adenome and carcinome in comparison 
with normal tissue. miR-135 family (miR-135a and 
miR-135b) overexpression during CRC progression 
(in patients) (Nagel et al., 2008). Consistently, a 
study comparing patient samples, healthy controls 
and cell lines showed overexpression in CRC 
samples (Zhou et al., 2012). Another study also 
showed overexpression associated with progression 
and metastasis (Vickers et al., 2012).  
Targets: Adenomatous polyposis coli (APC) 
(Nagel et al., 2008). Metastasis suppressor 1 
(MTSS1) (Zhou et al., 2012).  
Function: miR-135a and miR-135b inhibits APC 
translation (independently of mutational status of 
APC) activating downstream Wnt pathway activity 
and induce beta-catenin signaling (Nagel et al., 
2008). In CRC cell lines, miR-135a overexpression 
increased proliferation and promoted mobility and 




Tumor suppressor (Wu H et al., 2012).  
miRNA expression: Downregulation in gastric 
cancer patient samples in comparison with adjacent 
normal tissue.  
Targets: JAK2 (Janus kinase 2)  
Function: miR-135a overexpression produces 
downregulation of JAK2 levels reducing cell 
proliferation and colony formation. It also reduces 
p-STAT3 (phospho signal transducer and activator 
of transcription 3) activation and cyclin D1 and 
Bcl-x (BCL2-like1). 
Hepatocellular carcinoma (HCC) 
Prognosis 
In a cohort of 50 patients, overexpression of miR-
135a identified a group of patients with worse OS 
end DFS among patients with PVTT. 
Oncogenesis 
Oncogene (Liu et al., 2012).  
miRNA expression: Overexpression of miR-135a 
in samples from HCC with portal vein tumor 
thrombus (PVTT) - that is considered a special type 
of HCC metastasis - compared with parenchyma 
tumor nodes.  
Targets: MTSS  
Function: miR-135a promotes invasion and 
metastasis in vitro and in mouse models of HCC. 
Reducing miR-135a leads to reduced PVTT. The 
transcription of miR-135a is regulated by FOXM1. 
Breast cancer 
Oncogenesis 
Oncogene (Chen et al., 2012).  
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miRNA expression: Overexpression in metastasic 
breast tumors in comparison with benign tumor 
patient samples. Upregulation in the highly invasive 
breast cancer cell line BT 549 in comparison with 
other breast cancer cell lines. 
Targets: HOXA10 (homeobox A10).  
Function: miR-135a promotes the migration and 




Tumor suppressor (Wu S et al., 2012).  
miRNA expression: Downregulated in glioma in 
comparison with normal glia. miRNA-135a 
correlated negatively with the pathological grading 
of human glioma tissue samples. 
Targets: STAT6 (signal transducer and activator of 
transcription 6), SMAD5 (SMAD family member 
5), BMPR2 (bone morphogenetic protein receptor, 
type II). 
Function: miR-135a selectively induces 
mitochondria-dependent apoptosis of malignant 
glioma by targeting various genes (STAT6, 
SMAD5, BMPR2). Interestingly it doesn't affect 
normal glia cells. 
Lung cancer 
Oncogenesis 
Tumor suppressor (Cheng et al., 2013; Zhou et al., 
2013).  
miRNA expression: miR-135a/b downregulated in 
the cisplatin-resistant cell line A549R compared 
with the cisplatin-sensitive A549 cell line (Zhou, 
Qiu et al. 2013).  
Targets: MCL1 (myeloid cell leukemia sequence 
1) (Zhou et al., 2013), CD133 (Cheng et al., 2013).  
Function: Overexpression of miR-135a/b reduced 
MCL1 and sensitized cell lines to cisplatin by 
modulation of apoptosis (Zhou et al., 2013). miR-
135a/b suppressed CD133 only in CD133 with 
binding polymorphism rs2240688 CC or CA but 
not in genotype AA (Cheng et al., 2013). 
Classic Hodgkin lymphoma (cHL) 
Prognosis 
In a cohort of 89 cHL patients, low miR-135a was 
associated with a higher risk of relapse and worse 
disease free survival. 
Oncogenesis 
Tumor suppressor (Navarro et al., 2008; Navarro et 
al., 2009).  
miRNA expression: Downregulated miR-135a in 
cHL patient lymph nodes in comparison with 
reactive non-tumor lymph nodes used as control.  
Targets: JAK2. 
Function: Overexpression of miR-135a increases 
apoptosis and decreases cellular growth in HL cell 
lines through regulation of JAK/STAT pathway and 
activation BcL-xL expression. 
Acute myeloid leukemia (AML) 
Prognosis 
In a cohort of 85 intermediate risk AML (IR-AML) 
patients (later extended to 238 IR-AML patients), 
low expression of miR-135a identified a group of 
patients with a higher risk of relapse - both in the 
entire cohort and also within the unfavourable 
molecular subgroup (FLT3-ITD or wild-type NPM 
and CEBPA) (Díaz-Beyá et al., 2014). 
Oncogenesis 
Tumor suppressor. 
Renal cell carcinoma 
Oncogenesis 
Tumor suppressor (Hidaka et al., 2012).  
miRNA expression: Lower expression of miR-
135a observed in 10 cancer tissue samples 
compared to 5 adjacent non-cancer tissue samples. 
Function: Effect on cell proliferation, where the 
miR-135a overexpression reduces cell viavility. 
Cervival cancer cell 
Oncogenesis 
Oncogene (Leung et al., 2014).  
miRNA expression: miR-135a is overexpressed in 
cervical squamous cell carcinoma in comparison 
with cervical intraepithelial neoplasia (precancerous 
lesions).  
Targets: SIAH1 (in cervical cancer cells and 
cervical epithelial cells). 
Function: Overexpression of miR-135a induced 
increased colony formation, anchorage-independent 
growth, and proliferation, cell-invasion and 
migration in cervical cancer cell lines.  
The inhibition of miR-135a on SIAH1 led to 
upregulation of beta-catenin activity, indicating that 
miR-135a induces transformation and enhances 
tumor growth.  
The authors analyzed the miR-135a-induced 
malignant transformation activity in cell lines with 
or without human papiloma virus (HPV) proteins 
(E6 and E7) and concluded that these proteins are 
necessary for miR-135a oncogenic activity.  
Also in xenografts, miR-135a improved the growth 
of cancer cells and the tumorigenic activity of HPV 
cells. 
Various tumor cell lines (HeLa 
cervical carcinoma, SW480 colon 
cancer, A375 melanoma, PANC-1 
pancreatic tumor, and 293 epithelial 
kidney cells) 
Note 
FAK is overexpressed in many cancers. 
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Oncogenesis 
Tumor suppressor (Golubovskaya et al., 2014).  
Targets: FAK (focal adhesion kinase).  
Function: miR-135a overexpression decreased 
FAK mRNA and protein levels, decreased cell 
invasion and increased sensitivity to doxorubicin, 
5-fluorouacil and FAK inhibitor Y15. 
Various tumor cell lines 
Oncogenesis 
Oncogene (Holleman et al., 2011).  
miRNA expression: miR-135a levels were 
significantly upregulated in paclitaxel-resistant 
ovarian, lung, uterine, breast and prostate tumor 
cells lines derived from A549, PC-14, MCF-7, PC-
3, SKOV-3 and MES-SA. 
Targets: APC. 
Function: miR-135a upregulation in vitro and in 
vivo is associated with paclitaxel resistance. Anti-
miR-135a treatment in paclitaxel-resistant lung 
cancer xenografts restored sensitivity to paclitaxel, 





miRNA expression: Overexpression in diabetic 
human and mouse skeletal muscle.  
Targets: IRS2 (insulin receptor substrate 2). 
Function: miR-135a inhibits IRS2, thus reducing 
glucose uptake into the cell. miR-135a 
overexpression attenuates insulin signaling and 
glucose uptake in skeletal muscle. In vivo, silencing 





Targets: NR3C2 (mineral corticoid receptor).  
Function: In Hela cells, overexpression of miR-
135a and miR-124 downregulates NR3C2 protein, 
indicating a role in the regulation of blood pressure 
(Sõber et al., 2010). 
Corticoid dependent stress response 
Note 
Targets: NR3C2 (mineral corticoid receptor, other 
alias MR)  
Function: In a mouse model, downregulation of 
miR-135a and miR-124 in amygdale after two 
hours of stress stimulus.  
Stress reaction by activation of corticosteroid 
signaling through NR3C2R. miR-135a and miR-
124 are thus important components of the stress 
signaling response in the brain (Mannironi et al., 
2013). 




miRNA expression: In rat models, low expression 
of miR-135a in undescended testis in comparison 
with that in contralateral normal testis. Higher miR-
135a expression in the testes than in other organs. 
miR-135a is detected in spermatogonial stem cells. 
Targets: FoxO1 (forehead box protein O1). 
Functions: miR-135a contributes to 
spermatogonial stem cell maintenance through 
modulation of FoxO1 (Moritoki et al., 2014). 
Endometriosis 
Note 
miRNA expression: Overexpressed in 
endometriosis in comparison with normal 
endometrial tissue (50 controls and 32 women with 
endometriosis).  
Targets: HOXA10 (homeobox A10). 
Function: miR135a expression in controls was 
increased during the proliferative phase, decreased 
at the time of ovulation, and increased during the 
luteal phase (Petracco et al., 2011). 
Osteogenesis 
Note 
miRNA expression: Very low levels in 
differentiated osteoblast, downregulated during 
BMP2-mediated osteogenic differentiation.  
Targets: SMAD5.  
Function: miR-135a suppresses osteogenesis and 
inhibits differentiation of osteoprogenitors and the 
osteogenic phenotype in pluripotent cells by 
attenuating SMAD5. BMP2 inhibits miR-135a 
expression and permits osteoblast differentiation 
(Li et al., 2008). 
Muscle differentiation (myogenesis) 
and Duchenne muscular dystrophy 
(DMD) 
Note 
miRNA expression: miR-135a is upregulated 
during myogenic differentiation. Overexpression of 
miR-135a is observed when the myoblasts are 
differentiated in human samples, cell lines and 
mouse model (Greco et al., 2009). miR-135a is part 
of the DMD miRNA signature (Greco et al., 2009) 
and is overexpressed in Duchenne muscle (Cesana 
et al., 2011).  
Targets: MEF2C (myocyte enhancer factor 2C) 
(Cesana et al., 2011). 
Function: Critical in myogenesis by targeting 
MEF2C. miR-135a inhibits MEF2C, leading to 
inhibition of muscle genes. LincRNA MD1 sponges 
miR-135a, allowing transcription of muscle genes.  
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LincRNA MD1 is reduced in Duchenne muscle 
cells, so miR-135a is overexpressed and MEFC2 is 
downregulated (Cesana et al., 2011). 
Preimplantation embryo development 
Note 
miRNA expression: Overexpressed in mouse 
zygote and decreased thereafter, indicating that it is 
a zygote-specific miRNA.  
Targets: SIAH1A (E3 ubiquitin ligase seven in 
absentia homolog 1A).  
Function: miR-135a modulates the first cell 
cleavage through regulation of Siah1a. When miR-
135a is inhibited, first cell cleavage is suppressed. 
mir-135a regulates proteosomal degradation (Pang 
et al., 2011). 
Mouse embryonic stem cells 
Note 
miRNA expression: Upregulated during mouse 
embryonic stem cell differentiation.  
Targets: SIRT1 (sirtuin 1).  
Function: Together with miR-181a, miR-181b, 
miR-9, miR-204 and miR-199b, miR-135a 
suppressed SIRT1 protein expression during mouse 
embryonic stem cell differentiation (Saunders et al., 
2010). 
Bovine blastocyst development 
Note 
miRNA expression: miR-135a is part of a 
downregulated miRNA signature in more mature 
stage (Goossens et al., 2013). 
Megakaryocytopoiesis 
Note 
miRNA expression: A comparison between 
differentiated megakaryocytes with AML 
megakaryocytic cell lines found miR-135a higher in 
AML samples (Garzon et al., 2006). 
Hypoxia 
Note 
miRNA expression: Downregulation of miR-135a 
(and miR199a-5p) in response to hypoxia.  
Targets: FLAP (5-lipoxygenase activating protein) 
(Gonsalves and Kalra, 2010). 
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